NLRP3 and cryopyrin-associated periodic syndrome: In contrast, treatment with the NLRP3 inhibitor MCC950 (a.k.a. CRID3 or CP-456773) reduced the percentage of ASC-specking monocytes in both groups, with a marked reduction in CAPS patients (Supplementary Fig. 1).